Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/ BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib

MeSH terms

• Core Binding Factor Alpha 2 Subunit* / genetics
• Gene Rearrangement
• Humans
• Leukemia, Myeloid / drug therapy*
• Leukemia, Myeloid / genetics*
• Male
• Middle Aged
• Morpholines / therapeutic use*
• Mutation
• Pyrimidines / therapeutic use*
• Pyrroles / therapeutic use*
• Receptor, Fibroblast Growth Factor, Type 1 / genetics
• Translocation, Genetic